Anticoagulation in the management of venous thromboembolism in the cancer patient

Journal of Thrombosis and Thrombolysis

Volumn 31, Issue 3, 2011, Pages 282-294

  Streiff, Michael B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anticoagulation; Cancer; Prophylaxis; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER PATIENT; CATHETER THROMBOSIS; CHRONIC DRUG ADMINISTRATION; COMPRESSION GARMENT; CONFERENCE PAPER; CONTINUOUS INFUSION; CYTOPENIA; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CLEARANCE; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURGICAL RISK; THROMBOCYTOPENIA; VASCULARIZATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; NEOPLASMS; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM;

EID: 79958146171     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0562-0     Document Type: Conference Paper

References (84)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6):715-722. doi:10.1001/jama.293.6.715 (Pubitemid 40216041)
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd (2000) Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160(6):809-815 (Pubitemid 30165241)
3. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE (2006) Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119(1):60-68. doi:10.1016/j.amjmed.2005.06.058 (Pubitemid 43117468)
4. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458-464. doi:10.1001/.458
5. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3):529-535. doi:10.1111/j.1538-7836.2006.01804.x
6. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27(29):4839-4847. doi:10.1200/JCO.2009. 22.3271
7. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484-3488. doi:10.1182/blood-2002-01-0108 (Pubitemid 35303914)
8. Tapson VF, Decousus H, Pini M, Chong BH, Froehlich JB, Monreal M, Spyropoulos AC, Merli GJ, Zotz RB, Bergmann JF, Pavanello R, Turpie AG, Nakamura M, Piovella F, Kakkar AK, Spencer FA, Fitzgerald G, Anderson FA Jr, for the IMPROVE Investigators (2007) Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 132(3):936-945. doi:10.1378/chest.06-2993
9. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J (2003) Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8(4):381-388 (Pubitemid 36929723)
10. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, Moia M, Parazzini F, Rossi R, Sonaglia F, Valarani B, Bianchini C, Gussoni G (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89-95 (Pubitemid 43054059)
11. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83(1):14-19 (Pubitemid 30045469)
12. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with enoxaparin study group. N Engl J Med 341(11):793-800 (Pubitemid 29420474)
13. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110(7):874-879. doi:10.1161/01.CIR.0000138928.83266.24 (Pubitemid 39096017)
14. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW, ARTEMIS Investigators (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332(7537):325-329. doi:10.1136/bmj.38733.466748.7C
15. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group (2003) Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145(4):614-621. doi:10.1067/mhj.2003.189 (Pubitemid 36403489)
16. Streiff MB, National Comprehensive Cancer Center Network (2010) The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 125(Suppl 2):S128-S133. doi:10.1016/S0049-3848(10)70030-X
17. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB (2008) The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood. doi:10.1182/blood-2007-10-117051
18. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW (2007) American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490-5505. doi:10.1200/JCO.2007. 14.1283
19. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW, American College of Chest Physicians (2008) Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):381S-453S. doi:10.1378/chest.08-0656
20. Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104(12):2822-2829. doi:10.1002/cncr.21496 (Pubitemid 41798294)
21. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P (2006) Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 296(21):2558-2560. doi:10.1001/jama.296.21. 2558-c (Pubitemid 44903859)
22. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414-423. doi:10.1038/sj.leu.2405062 (Pubitemid 351255436)
23. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, PROTECHT Investigators (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10(10):943-949. doi:10.1016/S1470-2045(09)70232-3
24. Shah MM, Saif MW (2010) Pancreatic cancer and thrombosis. Highlights from the "2010 ASCO annual meeting". Chicago, IL, USA. June 4-8, 2010. JOP 11(4):331-333
25. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902-4907. doi:10.1182/blood-2007-10-116327
26. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I (2010) Prediction of venous thromboembolism in cancer patients. Blood 116(24):5377-5382. doi:10.1182/blood-2010-02-270116
27. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook DJ, Schunemann HJ (2008) Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 168(12):1261-1269. doi:10.1001/archinte.168. 12.1261 (Pubitemid 351930830)
28. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F, ENOXACAN II Investigators (2002) Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346(13):975-980. doi:10.1056/NEJMoa012385 (Pubitemid 34983247)
29. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, Nielsen JD, Horn A, Mohn AC, Somod L, Olsen B, FAME Investigators (2006) Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 4(11):2384-2390. doi:10.1111/j.1538-7836.2006.02153.x (Pubitemid 44575433)
30. Akl EA, Terrenato I, Barba M, Sperati F, Muti P, Schunemann HJ (2008) Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. Thromb Haemost 100(6):1176-1180
31. Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, Julian JA (2006) Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 24(9):1404-1408. doi:10.1200/JCO.2005.03.5600 (Pubitemid 46622005)
32. Evans RS, Sharp JH, Linford LH, Lloyd JF, Tripp JS, Jones JP, Woller SC, Stevens SM, Elliott CG, Weaver LK (2010) Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 138(4):803-810. doi:10.1378/chest.10-0154
33. Bern MM, Lokich JJ, Wallach SR, Bothe A Jr, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112(6):423-428 (Pubitemid 20098523)
34. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 75(2):251-253 (Pubitemid 26081476)
35. Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, Bazzan M, Parise P, Quintavalla R, Naglieri E, Santoro A, Imberti D, Soraru M, Mosca S (2005) Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23(18):4057-4062. doi:10.1200/JCO.2005.06.084
36. Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, Macleod D, Burton E, Andreou P, Anderson DR (2005) Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23(18):4063-4069. doi: 10.1200/JCO.2005.10.192 (Pubitemid 46211311)
37. Carrier M, Tay J, Fergusson D, Wells PS (2007) Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials. J Thromb Haemost 5(12):2552-2554. doi:10.1111/j.1538-7836.2007.02751.x (Pubitemid 350154369)
38. Akl EA, Kamath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook DJ, Schunemann HJ (2008) Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer. 112(11):2483-2492. doi: 10.1002/cncr.23479
39. Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, Shepherd S, Stanley A, Sweeney A, Wilde J, Wheatley K, WARP Collaborative Group U. (2009) Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 373(9663):567-574. doi:10.1016/S0140-6736(09)60205-1
40. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S, National Comprehensive Cancer Network (2008) Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6(8):716-753
41. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F, Schunemann HJ (2008) Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 113(7):1685-1694. doi:10.1002/cncr.23814
42. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349(18):1695-1702. doi:10.1056/NEJMoa035451 (Pubitemid 37315006)
43. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, Matisse Investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140(11):867-873
44. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Buller HR (2009) Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost 101(4):762-769
45. Shetty R, Seddighzadeh A, Parasuraman S, Vallurupalli NG, Gerhard-Herman M, Goldhaber SZ (2007) Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism. Thromb Haemost 98(6):1384-1386 (Pubitemid 350239118)
46. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162(15):1729-1735
47. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J, ONCENOX Investigators (2006) Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12(4):389-396. doi: 10.1177/1076029606293692 (Pubitemid 44359237)
48. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G, LITE Trial Investigators (2006) Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119(12):1062-1072. doi:10.1016/j.amjmed.2006.02. 022 (Pubitemid 44826932)
49. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146-153. doi:10.1056/NEJMoa025313 (Pubitemid 36818784)
50. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schunemann HJ (2008) Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 27:21. doi:10.1186/1756-9966- 27-21
51. Wittkowsky AK (2006) Barriers to the long-term use of lowmolecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 4(9):2090-2091. doi:10.1111/j.1538-7836.2006.02073.x
52. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Warfarin Optimal Duration Italian Trial Investigators (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345(3):165-169. doi:10.1056/NEJM200107193450302
53. Grogan KM, Wong C, Nutescu EA, Shord SS (2007) Examining differences in weekly warfarin dose in patients with and without cancer. Ther Drug Monit 29(5):638-643. doi:10.1097/FTD.0b013e318074dc46 (Pubitemid 47494064)
54. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians (2008) Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):454S-545S. doi:10.1378/chest.08-0658
55. Louzada ML, Lazo-Langner A, Dao V, Zhang J, Kovacs MJ, Carrier M, Rodger M, Wells P (2010) Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Blood 116(21):475a
56. Seddighzadeh A, Shetty R, Goldhaber SZ (2007) Venous thromboembolism in patients with active cancer. Thromb Haemost 98(3):656-661 (Pubitemid 47412893)
57. Munoz FJ, Mismetti P, Poggio R, Valle R, Barron M, Guil M, Monreal M, RIETE Investigators (2008) Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE registry. Chest 133(1):143-148. doi:10.1378/chest.07-1432
58. Linenberger ML (2006) Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 4(9):889-901
59. Ascher E, Salles-Cunha S, Hingorani A (2005) Morbidity and mortality associated with internal jugular vein thromboses. Vasc Endovascular Surg 39(4):335-339 (Pubitemid 41061700)
60. Kovacs MJ, Kahn SR, Rodger M, Anderson DR, Andreou R, Mangel JE, Morrow B, Clement AM, Wells PS (2007) A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 5(8):1650-1653. doi:10.1111/j.1538-7836.2007.02613.x
61. Tran H, Arellano M, Chamsuddin A, Flowers C, Heffner LT, Langston A, Lechowicz MJ, Tindol A, Waller E, Winton EF, Khoury HJ (2010) Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters. Leuk Lymphoma 51(8):1473-1477. doi: 10.3109/10428194.2010.481065
62. Monreal M, Falga C, Valdes M, Suarez C, Gabriel F, Tolosa C, Montes J, Riete Investigators (2006) Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 4(9):1950-1956. doi:10.1111/j.1538-7836.2006.02082.x
63. Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20(12):1907-1912. doi:10.1093/annonc/mdp369
64. Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162):1386-1389 (Pubitemid 29192409)
65. Kucher N, Rossi E, De Rosa M, Goldhaber SZ (2005) Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mmHg or higher. Arch Intern Med 165(15):1777-1781. doi:10.1001/archinte.165.15.1777 (Pubitemid 41138967)
66. Schoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ (2004) Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 110(20):3276-3280. doi:10.1161/01.CIR.0000147612.59751.4C (Pubitemid 39525077)
67. Vuilleumier N, Le Gal L, Verschuren F, Perrier A, Bounameaux H, Turck N, Sanchez JC, Mensi N, Perneger T, Hochstrasser D, Righini M (2009) Cardiac biomarkers for risk stratification in non-massive pulmonary embolism: a multicenter prospective study. J Thromb Haemost 7(3):391-398. doi:10.1111/j.1538-7836.2008.03260.x
68. Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF (2000) Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 84(4):548-552
69. Nendaz MR, Bandelier P, Aujesky D, Cornuz J, Roy PM, Bounameaux H, Perrier A (2004) Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thromb Haemost 91(6):1232-1236. doi:10.1267/THRO04061232 (Pubitemid 38821282)
70. Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ (2005) Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 172(8):1041-1046. doi:10.1164/rccm.200506- 862OC (Pubitemid 41476544)
71. Aujesky D, Roy PM, Le Manach CP, Verschuren F, Meyer G, Obrosky DS, Stone RA, Cornuz J, Fine MJ (2006) Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 27(4):476-481. doi:10.1093/eurheartj/ehi588 (Pubitemid 43209175)
72. Donze J, Le Gal G, Fine MJ, Roy PM, Sanchez O, Verschuren F, Cornuz J, Meyer G, Perrier A, Righini M, Aujesky D (2008) Prospective validation of the pulmonary embolism severity index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 100(5):943-948
73. Jimenez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD, RIETE Investigators. (2010) Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 170(15):1383-1389. doi: 10.1001/archinternmed.2010.199
74. Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A (2010) Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost. doi:10.1111/j.1538-7836.2010.03981.x
75. Erkens PM, Gandara E, Wells P, Shen AY, Bose G, Le Gal G, Rodger M, Prins MH, Carrier M (2010) Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost. doi: 10.1111/j.1538-7836.2010.04041.x
76. Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J, Laskin C, Fortin P, Anderson D, Kearon C, Clarke A, Geerts W, Forgie M, Green D, Costantini L, Yacura W, Wilson S, Gent M, Kovacs MJ (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349(12):1133-1138. doi:10.1056/NEJMoa035241 (Pubitemid 37122325)
77. Luk C, Wells PS, Anderson D, Kovacs MJ (2001) Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111(4):270-273 (Pubitemid 32885621)
78. Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY (2009) Dose escalation of low molecular weight heparin to manage recurrent venous thromboemblic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. doi: 10.1111/j.1538-7836.2009.03326.x
79. Varki A (2007) Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 110(6):1723-1729. doi:10.1182/blood-2006-10-053736
80. Cronin CG, Lohan DG, Keane M, Roche C, Murphy JM (2007) Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol 189(1):162-170. doi:10.2214/AJR.07.2067 (Pubitemid 46983207)
81. O'Connell CL, Boswell WD, Duddalwar V, Caton A, Mark LS, Vigen C, Liebman HA (2006) Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 24(30):4928-4932. doi:10.1200/JCO.2006.06.5870 (Pubitemid 46630922)
82. Lee EY, Kritsaneepaiboon S, Arellano CM, Grace RF, Zurakowski D, Boiselle PM (2010) Unsuspected pulmonary emboli in pediatric oncology patients: detection with MDCT. AJR Am J Roentgenol 194(5):1216-1222. doi:10.2214/AJR.09. 3463
83. Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Buller HR, Feragalli B, Porreca E (2010) Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 104(5):1049-1054. doi:10.1160/TH10-05-0277
84. O'Connell C, Razavi P, Ghalichi M, Boyle S, Vasan S, Mark L, Caton A, Duddalwar V, Boswell W, Grabow K, Liebman HA (2011) Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging MDCT scanning. J Thromb Haemost 9(2):305-311. doi:10.1111/j.1538-7836.2010. 04114.x